GRAL

#1921
GRAIL, Inc. Common Stock
52.0700 USD
-5.36%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
51.8200
52.2600
Range Annuel
41.5000
102.5200
Changement quotidien
-5.36%
Changement Mensuel
+6.27%
Evolution sur 6 mois
-47.40%
Changement Annuel
-47.40%
Clôture Précédente
55.0200
Ouvrir
52.2400
Plus Bas
51.8200
High
52.2600
Volume
21
Afficher le graphique complet

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
Compte de résultat Bilan Flux de trésorerie
Valeur Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

GRAIL Inc

GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021. In June 2021 GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.